Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
A bisphosphonate is a medicine that slows the breakdown and removal of bone. These drugs bind strongly to mineral in bone and are taken up by osteoclasts, the cells responsible for bone resorption. Reducing osteoclast activity can preserve bone density and lower fracture risk in appropriate patients. Examples include alendronate, risedronate, ibandronate, zoledronic acid, and pamidronate.
read more about bisphosphonate ...Bisphosphonates are commonly used to treat or prevent osteoporosis in patients at increased fracture risk. They are also used for Paget disease of bone, high calcium levels caused by cancer, and selected bone complications from cancer. The specific medicine, route, and treatment duration depend on the condition and risk level. Adequate calcium and vitamin D status are considered as part of treatment planning.
Bisphosphonates attach to hydroxyapatite at sites where bone is being remodeled. Osteoclasts absorb the drug when they break down the treated bone surface. Nitrogen-containing bisphosphonates inhibit an enzyme needed for normal osteoclast function, while older non-nitrogen drugs disrupt osteoclast activity through other mechanisms. The overall result is reduced bone resorption and slower bone turnover.
Bisphosphonates are available as oral tablets or liquids and as intravenous infusions or injections. Many oral products must be taken after an overnight fast with plain water, followed by remaining upright and avoiding food or other medicines for a specified period. These steps reduce esophageal irritation and improve absorption. Intravenous products follow different schedules and can require kidney-function, calcium, and vitamin D assessment.
Oral bisphosphonates can cause heartburn, esophageal irritation, abdominal discomfort, and difficulty swallowing. Intravenous doses can cause temporary fever, muscle aches, or flu-like symptoms, especially after the first infusion. Rare but serious risks include osteonecrosis of the jaw, atypical femur fracture, severe hypocalcemia, kidney injury, and eye inflammation. Treatment duration and the possibility of a monitored drug holiday are reviewed according to fracture risk and the specific product.
They mainly slow bone resorption rather than directly stimulating new bone formation. This allows bone formation to catch up and can improve bone density over time.
Remaining upright helps the tablet reach the stomach and reduces prolonged contact with the esophagus. The required period depends on the specific product.
It is a planned interruption considered for selected patients after a period of treatment when fracture risk is no longer high. It is not appropriate for every patient and requires continued reassessment.
Osteonecrosis of the jaw is a rare complication, with greater risk during high-dose cancer treatment and after invasive dental procedures. Dental health and planned procedures should be discussed before treatment.
Bisphosphonate. StatPearls (NCBI Bookshelf). https://www.ncbi.nlm.nih.gov/books/NBK470248/. Date Accessed August 6, 2026.
FOSAMAX (Alendronate Sodium Tablets): Prescribing Information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56. Date Accessed August 6, 2026.
RECLAST (Zoledronic Acid) Injection: Prescribing Information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021817s032lbl.pdf. Date Accessed August 6, 2026.
Bisphosphonate-Related Jaw Osteonecrosis. StatPearls (NCBI Bookshelf). https://www.ncbi.nlm.nih.gov/books/NBK534771/. Date Accessed August 6, 2026.
Pharmacological Management of Osteoporosis in Postmenopausal Women Guideline Resources. Endocrine Society. https://www.endocrine.org/clinical-practice-guidelines/osteoporosis-in-postmenopausal-women. Date Accessed August 6, 2026.